Ritonavir Patent Expiration
Ritonavir is Used for treating HIV infection in combination with other antiretroviral agents. It was first introduced by Abbvie Inc
Ritonavir Patents
Given below is the list of patents protecting Ritonavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Norvir |
US8470347 (Pediatric) | Self-emulsifying active substance formulation and use of this formulation | Mar 17, 2027 | Abbvie |
| Norvir | US8470347 | Self-emulsifying active substance formulation and use of this formulation | Sep 17, 2026 | Abbvie |
| Norvir |
US8268349 (Pediatric) | Solid pharmaceutical dosage form |
Feb 25, 2025
(Expired) | Abbvie |
| Norvir |
US8399015 (Pediatric) | Solid pharmaceutical dosage form |
Feb 25, 2025
(Expired) | Abbvie |
| Norvir |
US8691878 (Pediatric) | Solid pharmaceutical dosage form |
Feb 25, 2025
(Expired) | Abbvie |
| Norvir | US8268349 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Norvir | US8399015 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Norvir | US8691878 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Norvir |
US7364752 (Pediatric) | Solid dispersion pharamaceutical formulations |
May 10, 2021
(Expired) | Abbvie |
| Norvir |
US7141593 (Pediatric) | Pharmaceutical formulations |
Nov 22, 2020
(Expired) | Abbvie |
| Norvir |
US7432294 (Pediatric) | Pharmaceutical formulations |
Nov 22, 2020
(Expired) | Abbvie |
| Norvir | US7364752 | Solid dispersion pharamaceutical formulations |
Nov 10, 2020
(Expired) | Abbvie |
| Norvir | US7141593 | Pharmaceutical formulations |
May 22, 2020
(Expired) | Abbvie |
| Norvir | US7432294 | Pharmaceutical formulations |
May 22, 2020
(Expired) | Abbvie |
| Norvir |
US7148359 (Pediatric) | Polymorph of a pharmaceutical |
Jan 19, 2020
(Expired) | Abbvie |
| Norvir | US7148359 | Polymorph of a pharmaceutical |
Jul 19, 2019
(Expired) | Abbvie |
| Norvir |
US6232333 (Pediatric) | Pharmaceutical composition |
May 07, 2018
(Expired) | Abbvie |
| Norvir | US6232333 | Pharmaceutical composition |
Nov 07, 2017
(Expired) | Abbvie |
| Norvir |
US6037157 (Pediatric) | Method for improving pharmacokinetics |
Dec 26, 2016
(Expired) | Abbvie |
| Norvir |
US6703403 (Pediatric) | Method for improving pharmacokinetics |
Dec 26, 2016
(Expired) | Abbvie |
| Norvir | US6037157 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Abbvie |
| Norvir | US6703403 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Abbvie |
| Norvir |
US5648497 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 15, 2015
(Expired) | Abbott |
| Norvir |
US5648497 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 15, 2015
(Expired) | Abbvie |
| Norvir |
US5635523 (Pediatric) | Retroviral protease inhibiting compounds |
Dec 03, 2014
(Expired) | Abbott |
| Norvir |
US5484801 (Pediatric) | Pharmaceutical composition for inhibiting HIV protease |
Jul 28, 2014
(Expired) | Abbvie |
| Norvir | US5648497 | Retroviral protease inhibiting compounds |
Jul 15, 2014
(Expired) | Abbott |
| Norvir | US5648497 | Retroviral protease inhibiting compounds |
Jul 15, 2014
(Expired) | Abbvie |
| Norvir | US5635523 | Retroviral protease inhibiting compounds |
Jun 03, 2014
(Expired) | Abbott |
| Norvir |
US5948436 (Pediatric) | Pharmaceutical composition |
Mar 13, 2014
(Expired) | Abbott |
| Norvir |
US5948436 (Pediatric) | Pharmaceutical composition |
Mar 13, 2014
(Expired) | Abbvie |
| Norvir |
US5541206 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 30, 2014
(Expired) | Abbott |
| Norvir |
US5541206 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 30, 2014
(Expired) | Abbvie |
| Norvir |
US5635523 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 30, 2014
(Expired) | Abbvie |
| Norvir |
US5674882 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 30, 2014
(Expired) | Abbvie |
| Norvir | US5484801 | Pharmaceutical composition for inhibiting HIV protease |
Jan 28, 2014
(Expired) | Abbvie |
| Norvir | US5948436 | Pharmaceutical composition |
Sep 13, 2013
(Expired) | Abbott |
| Norvir | US5948436 | Pharmaceutical composition |
Sep 13, 2013
(Expired) | Abbvie |
| Norvir | US5541206 | Retroviral protease inhibiting compounds |
Jul 30, 2013
(Expired) | Abbott |
| Norvir | US5541206 | Retroviral protease inhibiting compounds |
Jul 30, 2013
(Expired) | Abbvie |
| Norvir | US5635523 | Retroviral protease inhibiting compounds |
Jul 30, 2013
(Expired) | Abbvie |
| Norvir | US5674882 | Retroviral protease inhibiting compounds |
Jul 30, 2013
(Expired) | Abbvie |
Ritonavir's Family Patents
Explore Our Curated Drug Screens
Ritonavir Generic API Manufacturers
Several generic applications have been filed for Ritonavir. The first generic version for Ritonavir was by Cipla Ltd and was approved on Jan 15, 2015. And the latest generic version is by Norvium Bioscience Llc and was approved on Feb 16, 2024.
Given below is the list of companies who have filed for Ritonavir generic, along with the locations of their manufacturing plants worldwide.
1. AMNEAL
Amneal Pharmaceuticals Llc has filed for 1 generic for Ritonavir. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet | Prescription | ORAL | AB | Sep 17, 2018 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
2. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 1 generic for Ritonavir. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet | Prescription | ORAL | AB | Sep 17, 2018 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
3. CIPLA
Cipla Ltd has filed for 1 generic for Ritonavir. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet | Prescription | ORAL | AB | May 10, 2022 |
Manufacturing Plant Locations New
Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
4. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 1 generic for Ritonavir. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet | Prescription | ORAL | AB | Sep 17, 2018 |
5. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Ritonavir. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | capsule | Discontinued | ORAL | N/A | Dec 3, 2020 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||
6. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 1 generic for Ritonavir. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | capsule | Prescription | ORAL | N/A | Feb 16, 2024 |